Liquid Biopsy Market

1. Market Research Future Liquid Biopsy Market by Value, Revenue, Segments, Mega trends, Prominent Players and Outlook to 2022 Liquid Biopsy Market - Scenario A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science namely human genome sequencing and rising sensitivity of detecting techniques and assays. Request Sample copy at https://www.marketresearchfuture.com/sample_request/710 The global Liquid Biopsy market is currently valued at $ 3950 million and will reach $ 17,372.28 million growing at a CAGR of 28%. The growth factors responsible for this explosive growth are liquid biopsy is a comparatively painless and non-invasive technique which provides early real time high precision detection of diseases which could be used for monitoring and designing effective treatment strategies based on the real time molecular assessment for the progression of the disease. Other factors driving the liquid biopsy market are lifestyle changes and environmental factors such as rising investment in research and development and collaborations between companies and public organizations, rise in population particularly geriatric population, rising expenditure on health etc. The technique also has other advantages over traditional tissue biopsy such as potential applications to cardiovascular diseases, autoimmune diseases etc. The restraints include the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. Also not all cancer patients benefit from early detection as some cancers such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample. Players Covered: Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, Exosome Diagnostics and others. Segmentation: Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end- users; market is segmented into hospitals and laboratories, academic and research centers and others. Regional Analysis of Liquid Biopsy Market:

2. Market Research Future Globally North America is the largest market for Global Liquid Biopsy market. Europe is the second-largest market for Global Liquid Biopsy market. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future. North America accounted for the largest market share of 37.95% in 2016 accounting for a market value of 1,499.10 million in 2016. Asia pacific is the fastest growing market which is growing at a CAGR of 28.8%. Browse Complete Report at https://www.marketresearchfuture.com/reports/liquid- biopsy-market-710 About US: Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Contact Us: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India Phone: +1 646 845 9312 Email: sales@marketresearchfuture.com